A randomized phase II/III study of paclitaxel/carboplatin/metformin versus paclitaxel/carboplatin/placebo as initial therapy for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer: An NRG Oncology/GOG study

Abstract

Peer reviewed

V.L. Bae-Jump, M. Sill, P.A. Gehrig, K. Moxley, A.R. Hagemann, S.E. Waggoner, R.E. O'Cearbhaill, M. McDonald, P.A. DiSilvestro, P. Sperduto, …

Gynecologic oncology, Vol.159, pp.7-7

10/2020

DOI: 10.1016/j.ygyno.2020.06.013

View Online

Title: Subtitle: A randomized phase II/III study of paclitaxel/carboplatin/metformin versus paclitaxel/carboplatin/placebo as initial therapy for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer: An NRG Oncology/GOG study
Creators: V.L. Bae-Jump - University of North Carolina at Chapel Hill
M. Sill - Gynecologic Oncology Group
P.A. Gehrig - University of North Carolina at Chapel Hill
K. Moxley - University of Oklahoma
A.R. Hagemann - Washington University in St. Louis
S.E. Waggoner - University Hospitals of Cleveland
R.E. O'Cearbhaill - Memorial Sloan Kettering Cancer Center
M. McDonald - University of Iowa
P.A. DiSilvestro - Women & Infants Hospital Brown University
P. Sperduto - Radiation Oncology Associates
C. Aghajanian - Memorial Sloan Kettering Cancer Center
Resource Type: Abstract
Publication Details: Gynecologic oncology, Vol.159, pp.7-7
Publisher: Elsevier Inc
DOI: 10.1016/j.ygyno.2020.06.013
ISSN: 0090-8258
eISSN: 1095-6859
Language: English
Date published: 10/2020
Academic Unit: Obstetrics and Gynecology
Record Identifier: 9984316891302771

23 Record Views